Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics

BMY POWR Grades

• Value is the dimension where BMY ranks best; there it ranks ahead of 99.18% of US stocks.
• BMY's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
• BMY ranks lowest in Momentum; there it ranks in the 10th percentile.

BMY Stock Summary

• BRISTOL MYERS SQUIBB CO's market capitalization of $106,417,829,907 is ahead of 97.74% of US-listed equities.
• BRISTOL MYERS SQUIBB CO's stock had its IPO on January 1, 1986, making it an older stock than 92.92% of US equities in our set.
• Of note is the ratio of BRISTOL MYERS SQUIBB CO's sales and general administrative expense to its total operating expenses; only 13.7% of US stocks have a lower such ratio.
• Stocks that are quantitatively similar to BMY, based on their financial statements, market capitalization, and price volatility, are ADI, GILD, ABNB, MELI, and VALE.
• BMY's SEC filings can be seen here. And to visit BRISTOL MYERS SQUIBB CO's official web site, go to www.bms.com.

BMY Valuation Summary

• BMY's EV/EBIT ratio is 15.6; this is 6.85% higher than that of the median Healthcare stock.
• Over the past 243 months, BMY's price/earnings ratio has gone down 7.2.

Below are key valuation metrics over time for BMY.

BMY Growth Metrics

The 4 year cash and equivalents growth rate now stands at 304.53%.
• Its 3 year net cashflow from operations growth rate is now at 163.12%.
• The 2 year net cashflow from operations growth rate now stands at 53.2%.

BMY's revenue has moved up $2.6194e+10 over the prior 70 months.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-12-31	46,159	13,066	6,327
2022-09-30	46,738	13,817	6,677
2022-06-30	47,144	15,396	6,617
2022-03-31	46,960	16,195	6,251
2021-12-31	46,385	16,207	6,994
2021-09-30	45,468	15,820	-5,405

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BMY has a Quality Grade of B, ranking ahead of 79.64% of graded US stocks.
• BMY's asset turnover comes in at 0.38 -- ranking 124th of 680 Pharmaceutical Products stocks.
• PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.